SCHEMBL432565

SCHEMBL432565

CC(=O)NCCCCC(C)NC(C)=O

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.58
MAPK1 P28482 1/20 0.58
HIF1A Q16665 1/20 0.58
FOLH1 Q04609 1/20 0.49
PAOX Q6QHF9 3/20 0.48
ADRA1A P35348 1/20 0.47
SIRT6 Q8N6T7 1/20 0.43
SIRT1 Q96EB6 1/20 0.43
SIRT5 Q9NXA8 2/20 0.42
TRPV1 Q8NER1 1/20 0.41
EPHX1 P07099 1/20 0.39
TSHR P16473 1/20 0.39
MTNR1A P48039 1/20 0.38
MTNR1B P49286 1/20 0.38
ALDH1A1 P00352 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ZDHHC7 Q9NXF8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13936433 1.00 KDM4E (0.58) KDM4EMAPK1HIF1AFOLH1PAOX
SCHEMBL13936432 1.00 KDM4E (0.58) KDM4EMAPK1HIF1AFOLH1PAOX
SCHEMBL13752055 0.85 KDM4E (0.50) KDM4EMAPK1HIF1AFOLH1PAOX
SCHEMBL17560257 0.85 KDM4E (0.46) KDM4EMAPK1HIF1AFOLH1PAOX
SCHEMBL14155671 0.84 KDM4E (0.44) KDM4EMAPK1HIF1AFOLH1PAOX
SCHEMBL12107463 0.81 KDM4E (0.46) KDM4EMAPK1HIF1AFOLH1PAOX
SCHEMBL4762422 0.81 KDM4E (0.65) KDM4EMAPK1HIF1AFOLH1PAOX
SCHEMBL14156359 0.81 CYP2C19 (0.41) KDM4EMAPK1HIF1APAOXSIRT6
SCHEMBL10408284 0.79 KDM4E (0.52) KDM4EMAPK1HIF1AFOLH1PAOX
SCHEMBL15981282 0.79 KDM4E (0.70) KDM4EMAPK1HIF1AFOLH1PAOX

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11739055-B2 Process for preparing diisocyanates based on lysine EVONIK OPERATIONS GMBH (DE) 2023-08-29 US disclosed
US-8853325-B2 Water-soluble polymer alkanals NEKTAR THERAPEUTICS (US) 2014-10-07 US disclosed
US-20120123065-A1 Hydrolytically Stable Maleimide-Terminated Polymers NEKTAR THERAPEUTICS (US) 2012-05-17 US disclosed
US-20120065429-A1 WATER-SOLUBLE POLYMER ALKANALS NEKTAR THERAPEUTICS (US) 2012-03-15 US disclosed
US-8106131-B2 Hydrolytically stable maleimide-terminated polymers NEKTAR THERAPEUTICS (US) 2012-01-31 US disclosed
US-8076412-B2 Water-soluble polymer alkanals NEKTAR THERAPEUTICS (US) 2011-12-13 US disclosed
US-7994272-B2 Maleamic acid polymer derivatives and their bioconjugates NEKTAR THERAPEUTICS (US) 2011-08-09 US disclosed
US-20110034737-A1 Water-Soluble Polymer Alkanals NEKTAR THERAPEUTICS (US) 2011-02-10 US disclosed
US-7838595-B2 high purity; storage stability; electrophilically activated polymer derivatives with aldehyde functionality for conjugating to biologically active molecules; drug-polymer conjugate; NEKTAR THERAPEUTICS (US) 2010-11-23 US disclosed
US-20100113329-A1 Maleamic Acid Polymer Derivatives and Their Bioconjugates NEKTAR THERAPEUTICS (US) 2010-05-06 US disclosed
US-7659361-B2 Maleamic acid polymer derivatives and their bioconjugates NEKTAR THERAPEUTICS (US) 2010-02-09 US disclosed
US-20090234070-A1 high purity; storage stability; electrophilically activated polymer derivatives with aldehyde functionality for conjugating to biologically active molecules; drug-polymer conjugate; NEKTAR THERAPEUTICS AL, CORPORATION (US) 2009-09-17 US disclosed
US-20090214472-A1 Interferon-beta polymer conjugates ENZON PHARMACEUTICALS INC. (NJ) 2009-08-27 US disclosed
US-20090012241-A1 Hydrolytically stable maleimide-terminated polymers NEKTAR THERAPEUTICS AL, CORPORATION (US) 2009-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11739055-B2 Process for preparing diisocyanates based on lysine KDM7A, KDM8, JMJD6 KDM4E 19/4885MAPK1 1917/4885HIF1A 1383/4885
US-20120065429-A1 WATER-SOLUBLE POLYMER ALKANALS ALK, ALKBH3, AQP1 KDM4E 1616/4885MAPK1 3891/4885HIF1A 1407/4885
US-20100113329-A1 Maleamic Acid Polymer Derivatives and Their Bioconjugates F13A1, ASS1, PSAT1 KDM4E 2835/4885MAPK1 4065/4885HIF1A 1688/4885
US-20110034737-A1 Water-Soluble Polymer Alkanals ALK, ALKBH3, AQP1 KDM4E 1616/4885MAPK1 3891/4885HIF1A 1407/4885
US-20090214472-A1 Interferon-beta polymer conjugates IFNG, IFNAR1, STING1 KDM4E 4779/4885MAPK1 4548/4885HIF1A 2317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.